Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10622511 | 0.87 | ALDH1A1 (0.63) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL341786 | 0.85 | ALDH1A1 (0.61) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2030599 | 0.84 | ALDH1A1 (0.70) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL14817542 | 0.84 | ALDH1A1 (0.59) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL1114850 | 0.84 | CYP3A4 (0.54) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL21459089 | 0.84 | ALDH1A1 (0.46) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL8516064 | 0.84 | ALDH1A1 (0.59) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL3837959 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2605685 | 0.82 | ALDH1A1 (0.58) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL19026667 | 0.82 | ALDH1A1 (0.58) | ALDH1A1GLATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865742-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium | MAPI PHARMA LTD. (IL) | 2014-10-21 | — | — | US | claimed |
| EP-2642855-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | Mapi Pharma Limited (IL) | 2013-10-02 | — | — | EP | claimed |
| US-20130245065-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2013-09-19 | — | — | US | claimed |
| WO-2012070051-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2012-05-31 | — | — | WO | claimed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-9102592-B2 | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium | MAPI PHARMA LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | MAPI PHARMA LTD. (IL) | 2015-02-19 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| EP-1957498-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | MethylGene Inc. (CA) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051419-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | TLR7, NQO1, NQO2 | ALDH1A1 246/4885GLA 2702/4885TSHR 4706/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | ALDH1A1 1649/4885GLA 2918/4885TSHR 396/4885 |
| US-20130245065-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF QUINOLINE DERIVATIVES SUCH AS LAQUINIMOD SODIUM | TLR7, NQO1, NQO2 | ALDH1A1 246/4885GLA 2702/4885TSHR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.